Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
autx-703
- Development stage
- Phase 1
- Lead developer
- Auron Therapeutics
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
AUTX-703 is a novel, first-in-class, orally bioavailable small molecule degrader targeting the histone acetyltransferases Lysine acetyltransferase 2A (KAT2A) and Lysine acetyltransferase 2B (KAT2B). Developed by Auron Therapeutics using its AURIGIN platform, it is designed to modulate cell-state plasticity in cancer. Preclinical studies have demonstrated that AUTX-703 selectively and potently degrades KAT2A/B proteins, inhibits tumor growth, induces differentiation of cancer cells, and provides significant survival advantages in models of acute myeloid leukemia (AML), small cell lung cancer (SCLC), and neuroendocrine prostate cancer (NEPC). The drug has received FDA Fast Track designation for relapsed or refractory acute myelogenous leukemia (AML) and entered phase 1 clinical trials for hematological malignancies in early 2025[1][2][3][4][5][6].
- Other names
- AUTX 703AUTX703AUTX-703
02
Targets
KAT2A (Lysine acetyltransferase 2A)KAT2B
Beyond the preview
Go deeper on autx-703.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on autx-703.